$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000071913522000020 Filed on March 17, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$16.82M	$48.52M	$11.46M
YoY Change	46.81%	75.08%	36.72%
Cost Of Revenue	$4.673M	$14.92M	$3.760M
YoY Change	24.28%	46.14%	57.98%
Gross Profit	$12.15M	$33.60M	$7.700M
YoY Change	57.81%	91.96%	38.41%
Gross Profit Margin	72.22%	69.26%	67.19%
Selling, General & Admin	$12.90M	$18.62M	$8.840M
YoY Change	45.88%	59.3%	-19.05%
% of Gross Profit	106.13%	55.41%	114.81%
Research & Development	$947.0K	$4.321M	$920.0K
YoY Change	2.93%	10.23%	-16.36%
% of Gross Profit	7.79%	12.86%	11.95%
Depreciation & Amortization	$229.0K	$903.0K	$230.0K
YoY Change	-0.43%	1.8%	-4.17%
% of Gross Profit	1.88%	2.69%	2.99%
Operating Expenses	$13.84M	$48.05M	$9.760M
YoY Change	41.83%	27.83%	-18.8%
Operating Profit	-$1.692M	-$14.45M	-$2.060M
YoY Change	-17.86%	-28.06%	-68.1%
Interest Expense	$1.000K	$10.00K	$0.00
YoY Change		-78.26%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$185.0K	-$372.0K	$130.0K
YoY Change	-242.31%	-155.19%	-136.11%
Pretax Income	-$1.876M	-$14.82M	-$1.920M
YoY Change	-2.29%	-23.64%	-68.32%
Income Tax	$134.0K	$380.0K	$3.270M
% Of Pretax Income
Net Earnings	-$2.003M	-$15.17M	-$1.530M
YoY Change	30.92%	27.54%	-73.67%
Net Earnings / Revenue	-11.91%	-31.27%	-13.35%
Basic Earnings Per Share		-$0.44
Diluted Earnings Per Share	-$58.27K	-$0.44	-$44.65K
COMMON SHARES
Basic Shares Outstanding	34.34M shares	34.33M shares	34.27M shares
Diluted Shares Outstanding		34.33M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.87M	$30.87M	$41.90M
YoY Change	-26.32%	-26.36%	-28.74%
Cash & Equivalents	$30.87M	$30.87M	$41.92M
Short-Term Investments
Other Short-Term Assets	$1.926M	$1.826M	$2.800M
YoY Change	-31.21%	-34.79%	-22.22%
Inventory	$6.778M	$6.778M	$4.051M
Prepaid Expenses
Receivables	$13.04M	$13.14M	$8.399M
Other Receivables	$483.0K	$8.125M	$1.275M
Total Short-Term Assets	$60.74M	$60.74M	$66.09M
YoY Change	-8.1%	-8.1%	-13.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.575M	$6.874M	$6.541M
YoY Change	0.52%	-4.79%	-1.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.110M	$1.110M	$807.0K
YoY Change	37.55%	37.04%	106.39%
Total Long-Term Assets	$7.984M	$7.984M	$8.022M
YoY Change	-0.47%	-0.45%	0.12%
TOTAL ASSETS
Total Short-Term Assets	$60.74M	$60.74M	$66.09M
Total Long-Term Assets	$7.984M	$7.984M	$8.022M
Total Assets	$68.72M	$68.72M	$74.11M
YoY Change	-7.27%	-7.27%	-12.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.631M	$2.631M	$1.511M
YoY Change	74.12%	74.24%	-38.02%
Accrued Expenses	$10.29M	$8.546M	$7.278M
YoY Change	41.34%	48.63%	-22.54%
Deferred Revenue	$533.0K		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$165.0K	$165.0K	$200.0K
YoY Change	-17.5%	-31.25%	-50.0%
Total Short-Term Liabilities	$13.21M	$13.21M	$9.153M
YoY Change	44.27%	44.32%	-25.65%
LONG-TERM LIABILITIES
Long-Term Debt	$18.00K	$18.00K	$200.0K
YoY Change	-91.0%	-90.0%	-50.0%
Other Long-Term Liabilities	$166.0K	$1.489M	$166.0K
YoY Change	0.0%	61.85%	45.61%
Total Long-Term Liabilities	$166.0K	$1.507M	$166.0K
YoY Change	0.0%	37.0%	45.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.21M	$13.21M	$9.153M
Total Long-Term Liabilities	$166.0K	$1.507M	$166.0K
Total Liabilities	$14.71M	$15.02M	$10.25M
YoY Change	43.5%	44.53%	-23.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.55M		$2.621M
YoY Change	-578.86%		-81.95%
Common Stock	$34.00K		$34.00K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.70M	$53.70M	$63.72M
YoY Change
Total Liabilities & Shareholders Equity	$68.72M	$68.72M	$74.11M
YoY Change	-7.27%	-7.27%	-12.55%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$2.003M	-$15.17M	-$1.530M
YoY Change	30.92%	27.54%	-73.67%
Depreciation, Depletion And Amortization	$229.0K	$903.0K	$230.0K
YoY Change	-0.43%	1.8%	-4.17%
Cash From Operating Activities	$214.0K	-$10.45M	-$1.020M
YoY Change	-120.98%	-34.96%	-68.71%
INVESTING ACTIVITIES
Capital Expenditures	-$332.0K	$723.0K	-$390.0K
YoY Change	-14.87%	24.44%	77.27%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$332.0K	-$723.0K	-$390.0K
YoY Change	-14.87%	24.44%	69.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-39.00K	$24.00K	-130.0K
YoY Change	-70.0%	-132.88%
NET CHANGE
Cash From Operating Activities	214.0K	-$10.45M	-1.020M
Cash From Investing Activities	-332.0K	-$723.0K	-390.0K
Cash From Financing Activities	-39.00K	$24.00K	-130.0K
Net Change In Cash	-157.0K	-$11.05M	-1.540M
YoY Change	-89.81%	-34.63%	-55.87%
FREE CASH FLOW
Cash From Operating Activities	$214.0K	-$10.45M	-$1.020M
Capital Expenditures	-$332.0K	$723.0K	-$390.0K
Free Cash Flow	$546.0K	-$11.17M	-$630.0K
YoY Change	-186.67%	-32.89%	-79.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	0-12183
CY2021	dei	Entity Registrant Name EntityRegistrantName	APYX MEDICAL CORPORATION
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2644611
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	5115 Ulmerton Road
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Clearwater
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33760
CY2021	dei	City Area Code CityAreaCode	727
CY2021	dei	Local Phone Number LocalPhoneNumber	384-2323
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $.001 Par Value
CY2021	dei	Trading Symbol TradingSymbol	APYX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	353900000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34428487	shares
CY2021	dei	Auditor Firm AuditorFirmId	49
CY2021	dei	Auditor Location AuditorLocation	Orlando, Florida
CY2021	dei	Auditor Name AuditorName	RSM US LLP
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30870000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41915000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	430000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13038000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8399000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7642000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7654000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	483000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1275000	USD
CY2021Q4	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	263000	USD
CY2020Q4	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	388000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	6778000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4051000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1926000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2795000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	60737000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	66089000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6575000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6541000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	121000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	237000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	178000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	437000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1110000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	807000	USD
CY2021Q4	us-gaap	Assets Assets	68721000	USD
CY2020Q4	us-gaap	Assets Assets	74111000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2631000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1511000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61066000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12551000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10287000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7278000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	126000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	165000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	238000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13205000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9153000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	183000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1323000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	621000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	166000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	166000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	14712000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	10252000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34409912	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34409912	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34289222	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34289222	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66221000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2621000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	53704000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	63721000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	305000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	138000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54009000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63859000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68721000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74111000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48517000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27711000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14916000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10207000	USD
CY2021	us-gaap	Gross Profit GrossProfit	33601000	USD
CY2020	us-gaap	Gross Profit GrossProfit	17504000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4321000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3920000	USD
CY2021	us-gaap	Professional Fees ProfessionalFees	7589000	USD
CY2020	us-gaap	Professional Fees ProfessionalFees	7350000	USD
CY2021	us-gaap	Salaries And Wages SalariesAndWages	17522000	USD
CY2020	us-gaap	Salaries And Wages SalariesAndWages	14630000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18617000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11687000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	48049000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	37587000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-14448000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-20083000	USD
CY2021	us-gaap	Interest Income Operating InterestIncomeOperating	11000	USD
CY2020	us-gaap	Interest Income Operating InterestIncomeOperating	241000	USD
CY2021	us-gaap	Interest Expense InterestExpense	10000	USD
CY2020	us-gaap	Interest Expense InterestExpense	46000	USD
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-373000	USD
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	479000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-372000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	674000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14820000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19409000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	380000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7503000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-15200000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-11906000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-28000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15172000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11896000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2020	us-gaap	Profit Loss ProfitLoss	-11906000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34332000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34332000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34212000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34212000	shares
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71259000	USD
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	148000	USD
CY2020	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	148000	shares
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4210000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-11906000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63859000	USD
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	195000	USD
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	67000	shares
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5088000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-15200000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54009000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-15200000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	903000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	887000	USD
CY2021	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	109000	USD
CY2020	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	506000	USD
CY2021	us-gaap	Product Warranty Expense ProductWarrantyExpense	318000	USD
CY2020	us-gaap	Product Warranty Expense ProductWarrantyExpense	215000	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-48000	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-13000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5088000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4210000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	128000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	262000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4901000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	558000	USD
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-12000	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	7228000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1355000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	27000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2859000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-615000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1154000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-965000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3396000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2090000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10449000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16066000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	723000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	581000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-723000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-581000	USD
CY2021	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	67000	USD
CY2020	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	148000	USD
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	140000	USD
CY2021	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	238000	USD
CY2020	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	229000	USD
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	195000	USD
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	148000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-73000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-177000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11045000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16897000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41915000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58812000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30870000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41915000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	10000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	46000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	111000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	82000	USD
CY2021	apyx	Non Cash Transfer Of Other Assets To Fixed Assets NonCashTransferOfOtherAssetsToFixedAssets	43000	USD
CY2020	apyx	Non Cash Transfer Of Other Assets To Fixed Assets NonCashTransferOfOtherAssetsToFixedAssets	0	USD
CY2021	apyx	Non Cash Transfers Of Inventory To From Fixed Assets NonCashTransfersOfInventoryToFromFixedAssets	0	USD
CY2020	apyx	Non Cash Transfers Of Inventory To From Fixed Assets NonCashTransfersOfInventoryToFromFixedAssets	23000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div>
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	400000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1300000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	800000	USD
CY2018Q3	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	97000000	USD
CY2019Q4	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	357000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3603000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2243000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1441000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1109000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1997000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1087000	USD
CY2021Q4	us-gaap	Inventory Gross InventoryGross	7041000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	4439000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	263000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	388000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	6778000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4051000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	400000	USD
CY2020	apyx	Inventory Write Down Reversals InventoryWriteDownReversals	100000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11237000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10931000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5316000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4813000	USD
CY2021Q4	apyx	Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations	5921000	USD
CY2020Q4	apyx	Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations	6118000	USD
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment	654000	USD
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment	423000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6575000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6541000	USD
CY2021	us-gaap	Depreciation Depreciation	700000	USD
CY2020	us-gaap	Depreciation Depreciation	700000	USD
CY2021	apyx	Lessee Discount Rate Incremental Borrowing Rate LesseeDiscountRateIncrementalBorrowingRate	0.0400
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	134000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	124000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	216000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	216000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	12000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	22000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	12000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	13000	USD
CY2021	us-gaap	Lease Cost LeaseCost	374000	USD
CY2020	us-gaap	Lease Cost LeaseCost	375000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	135000	USD
CY2021	apyx	Finance Lease Payments FinanceLeasePayments	228000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	110000	USD
CY2020	apyx	Finance Lease Payments FinanceLeasePayments	251000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0398
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0400
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0403
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0400
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	610000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	125000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	168000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	0	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	18000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	125000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	186000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	3000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	122000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	183000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	165000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18000	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	546000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	808000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2117000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	811000	USD
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1656000	USD
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1001000	USD
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	593000	USD
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	498000	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	435000	USD
CY2021Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1027000	USD
CY2020Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1027000	USD
CY2021Q4	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1863000	USD
CY2020Q4	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1658000	USD
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	428000	USD
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	591000	USD
CY2021Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	1447000	USD
CY2020Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	449000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10287000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7278000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	200000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	600000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	500000	USD
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	498000	USD
CY2019Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	452000	USD
CY2021	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	318000	USD
CY2020	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	215000	USD
CY2021	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	223000	USD
CY2020	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	169000	USD
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	593000	USD
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	498000	USD
CY2021Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1000000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1900000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	500000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	100000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15172000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11896000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34332000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34332000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34212000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34212000	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	217000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-3682000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	54000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-120000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	109000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-37000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	380000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-3839000	USD
CY2021	apyx	Cares Act Income Tax Expense Benefit Valuation Allowance CARESActIncomeTaxExpenseBenefitValuationAllowance	0	USD
CY2020	apyx	Cares Act Income Tax Expense Benefit Valuation Allowance CARESActIncomeTaxExpenseBenefitValuationAllowance	3664000	USD
CY2021	apyx	Current Income Tax Expense Benefit After Valuation Allowance CurrentIncomeTaxExpenseBenefitAfterValuationAllowance	380000	USD
CY2020	apyx	Current Income Tax Expense Benefit After Valuation Allowance CurrentIncomeTaxExpenseBenefitAfterValuationAllowance	-7503000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2518000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-25000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-613000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1004000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3131000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1029000	USD
CY2021	apyx	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	-3131000	USD
CY2020	apyx	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	-1029000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	380000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7503000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.211
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.053
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.018
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.017
CY2021	apyx	Effective Income Tax Rate Reconciliation Section162m Compensation Percent EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent	-0.038
CY2020	apyx	Effective Income Tax Rate Reconciliation Section162m Compensation Percent EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent	0
CY2021	apyx	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGILTIPercent	-0.012
CY2020	apyx	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGILTIPercent	0
CY2021	apyx	Effective Income Tax Rate Reconciliation Cares Act Net Operating Loss Carryforwards Percent EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent	0
CY2020	apyx	Effective Income Tax Rate Reconciliation Cares Act Net Operating Loss Carryforwards Percent EffectiveIncomeTaxRateReconciliationCARESActNetOperatingLossCarryforwardsPercent	0.189
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.026
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.387
CY2021Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	4256000	USD
CY2020Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	1888000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1701000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1603000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	555000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	886000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	745000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7398000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4236000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6968000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3837000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	430000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	399000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	205000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	278000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	225000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	121000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	430000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	399000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q1	apyx	Cares Act Income Tax Expense Benefit Release Of Valuation Allowance Federal Net Operating Loss Carryforwards CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards	-3700000	USD
CY2020	apyx	Cares Act Effective Income Tax Rate Reconciliation Federal Net Operating Loss Carryforwards Amount CARESActEffectiveIncomeTaxRateReconciliationFederalNetOperatingLossCarryforwardsAmount	3700000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1300000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1300000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	600000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	400000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3966858	shares
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1313000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1313000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1313000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1313000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.95
CY2021	apyx	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P3Y
CY2021	apyx	Defined Contribution Plan Requisite Service Period DefinedContributionPlanRequisiteServicePeriod	P3M
CY2021	apyx	Defined Contribution Plan Employers Matching Contribution Vesting Percentage After Three Years DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	USD
CY2019Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	100000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	4900000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.67
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1376900	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.94
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	112965	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.37
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	291850	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.19
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4938943	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.46
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	894980	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.37
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	232521	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.65
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	203711	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.27
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5397691	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
CY2021	apyx	Share Based Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	5150000	USD
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2044469	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.61
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	894980	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.76
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	952332	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.49
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	184901	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	5.21
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1802216	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.21
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.689
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.708
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.659
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.701
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y6M
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5088000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4210000	USD
CY2021Q4	apyx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Intrinsic Value Closing Stock Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice	12.82
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5037248	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	35560000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.76
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3595475	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	29460000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.63
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1600000	USD
CY2020	apyx	Share Based Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	6580000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.76
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.78
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4270000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2510000	USD
CY2021	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	111831	shares
CY2020	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	39448	shares
CY2021	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	107357	shares
CY2020	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	47088	shares
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5010000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48517000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-14448000	USD
CY2021	us-gaap	Interest Income Operating InterestIncomeOperating	11000	USD
CY2021	us-gaap	Interest Expense InterestExpense	10000	USD
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-373000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	380000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27711000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-20083000	USD
CY2020	us-gaap	Interest Income Operating InterestIncomeOperating	241000	USD
CY2020	us-gaap	Interest Expense InterestExpense	46000	USD
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	479000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7503000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48517000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27711000	USD

Files In Submission

Name	View Source	Status
0000719135-22-000020-index-headers.html	Edgar Link	pending
0000719135-22-000020-index.html	Edgar Link	pending
0000719135-22-000020.txt	Edgar Link	pending
0000719135-22-000020-xbrl.zip	Edgar Link	pending
a2021q410-qexhibit311.htm	Edgar Link	pending
a2021q410-qexhibit312.htm	Edgar Link	pending
a2021q410-qexhibit321.htm	Edgar Link	pending
a2021q410-qexhibit322.htm	Edgar Link	pending
apyx-20211231.htm	Edgar Link	pending
apyx-20211231.xsd	Edgar Link	pending
apyx-20211231_cal.xml	Edgar Link	unprocessable
apyx-20211231_def.xml	Edgar Link	unprocessable
apyx-20211231_g1.jpg	Edgar Link	pending
apyx-20211231_g2.jpg	Edgar Link	pending
apyx-20211231_htm.xml	Edgar Link	completed
apyx-20211231_lab.xml	Edgar Link	unprocessable
apyx-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
listofsubsidiaries.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rsmconsent.htm	Edgar Link	pending
rsmconsent001.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2021 Q4 Form 10-K Financial Statement

#000071913522000020 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2021 Q4 Form 10-K Financial Statement

#000071913522000020 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx